Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7972627 | 0.82 | SMN1; SMN2 (0.38) | PPARASMN1; SMN2PPARDPPARG | |
| SCHEMBL7520112 | 0.81 | FBP1 (0.38) | PPARAFBP1CYP3A4PPARDPPARG | |
| SCHEMBL7974210 | 0.77 | ADORA1 (0.41) | PPARASMN1; SMN2PPARDPTGDR2PPARG | |
| SCHEMBL7974243 | 0.72 | SMN1; SMN2 (0.48) | PPARASMN1; SMN2PPARDPTGDR2PPARG | |
| SCHEMBL7976497 | 0.71 | MAPT (0.47) | PPARASMN1; SMN2CYP3A4PPARG | |
| SCHEMBL7976456 | 0.69 | PPARA (0.39) | PPARASMN1; SMN2PPARG | |
| SCHEMBL7976453 | 0.69 | SMN1; SMN2 (0.42) | PPARASMN1; SMN2PPARDPTGDR2PPARG | |
| SCHEMBL7962751 | 0.66 | MAPT (0.46) | PPARASMN1; SMN2FBP1CYP3A4PPARG | |
| SCHEMBL7962810 | 0.66 | MAPT (0.47) | PPARASMN1; SMN2FBP1CYP3A4PPARG | |
| SCHEMBL4815922 | 0.64 | SMN1; SMN2 (0.53) | PPARASMN1; SMN2PPARDPTGDR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |